Liver/Biliary Disorders News

Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.

Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.

Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress.

A home-based, prehabilitation program for liver transplant candidates that included financial incentives and text reminders increased walking by one-third over baseline, according to data presented at EASL Congress.

SAN DIEGO — Diabetes and nonalcoholic fatty liver disease are “common bedfellows” due to processes brought on by insulin resistance, but a reduction in dietary sugars combined with exercise can reverse the damage, according to a speaker.

Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress.

Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.

Among patients with alcoholic-related liver disease in early stages, 15% progressed to decompensation and 22% died within 6 years, according to data presented at EASL Congress.

In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.

  The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.